Chitosan derivatives, compositions and related methods of use

Inventors

Baker, Shenda • Wiesmann, William P. • Townsend, Stacy

Assignees

Synedgen Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-8916542-B2

Patent

Publication Date

2014-12-23

Expiration Date


Abstract

Described herein are methods and compositions using chitosan derivatives to treat and/or inhibit acquisition of multiple drug resistance (MDR). Also described herein are methods and compositions using chitosan derivatives in combination with an antibacterial agent to treat a bacterial infection and/or inhibit growth of bacteria, for example, resulting in a synergistic or sensitizing effect.

Core Innovation

The invention relates to methods of inhibiting the growth of a bacterium or killing a bacterium in a subject by contacting the bacterium with a derivatized chitosan and an anti-bacterial agent in an effective combined amount. The anti-bacterial agent and the derivatized chitosan are present at concentrations, or administered at doses, that result in a fractional inhibitory concentration (FIC) of less than or equal to 0.5. The derivatized chitosan comprises a chitosan of formula (I), including an integer n and R1 substituents selected from hydrogen and acetyl, with defined substitution criteria.

The derivatized chitosan is further defined by compositional constraints, including that at least 25% of R1 substituents are H, at least 1% of R1 substituents are acetyl, and at least 2% of R1 substituents are additionally substituted as defined by formula (I) or formula (II). Structural embodiments include derivatized, soluble chitosan derivatives with amino/guanidino or side-chain substituent embodiments, including chitosan-arginine. The document also recites quantitative structural specifications and physicochemical profile such as molecular weight ranges, polydispersity index, and degree of deacetylation (DDA).

The described derivatized chitosan structures are connected to antibacterial activity, including use against MDR bacteria such as MRSA and other listed bacterial species. The document further describes combination and synergy concepts in which the derivatized chitosan is used together with an anti-bacterial agent at concentrations or doses resulting in FIC of less than or equal to 0.5, including synergy and sensitization of resistant bacteria, and references effects such as biofilm viscosity reduction and surface, wound dressing, medical device, and cystic fibrosis (CF) lung biofilm related applications.

Claims Coverage

The independent claim is directed to a method of inhibiting growth or killing bacteria via a combined contacting step using a derivatized chitosan and an anti-bacterial agent, constrained to a synergy condition expressed by FIC ≤ 0.5. The claim coverage further includes structural constraints on the derivatized chitosan and additional quantitative and selection features.

Combined contacting using derivatized chitosan with FIC ≤ 0.5

A method of inhibiting the growth of a bacterium or killing a bacterium in a subject by contacting the bacterium with a derivatized chitosan and an anti-bacterial agent in an effective combined amount, where the anti-bacterial agent and derivatized chitosan are present at concentrations or administered at doses that result in a fractional inhibitory concentration (FIC) ≤ 0.5.

Derivatized chitosan of formula (I) with defined R1 substitution thresholds

The derivatized chitosan comprises a chitosan of formula (I) with each R1 independently selected from hydrogen and acetyl, where at least 25% of R1 substituents are H, at least 1% of R1 substituents are acetyl, and at least 2% of R1 substituents are additionally substituted as defined by formula (I) or formula (II).

Synergy requiring enhanced inhibition relative to each component alone

The method is configured such that the inhibition is at least 2 times greater than the combined inhibition achieved by using either the anti-bacterial agent or the derivatized chitosan alone.

Quantitative bactericidal effectiveness improvement (at least 2 logs)

The method includes an anti-bacterial agent and derivatized chitosan at a specified concentration or dose to achieve bactericidal activity that is at least 2 logs more effective than when either is absent.

Molecular weight constraint for the derivatized chitosan

The derivatized chitosan has a molecular weight between 25 and 100 kDa.

Polydispersity index constraint for the derivatized chitosan

The derivatized chitosan has a polydispersity index in the range of 1.0 to 2.5.

Named antibacterial agent selection against a specified bacterium

The method uses an antibacterial agent selected from Ciprofloxacin, Rifampicin, Neomycin, silver, or Gentamicin against the bacterium Pseudomonas aeruginosa.

Overall, the claim coverage centers on a combined antibacterial method using a derivatized chitosan of formula (I) with defined R1 substitution thresholds, used with an anti-bacterial agent so that the combination yields FIC ≤ 0.5, and further refined by quantitative superiority metrics and by specific derivatized chitosan physicochemical constraints and named antibacterial agent/bacterium pairings.

Stated Advantages

Achieves inhibition of bacterial growth or killing of a bacterium using a combined amount of derivatized chitosan and an anti-bacterial agent.

Combination provides synergy such that fractional inhibitory concentration (FIC) is less than or equal to 0.5.

Inhibition is at least 2 times greater than the combined inhibition achieved by either component alone.

Bactericidal activity is at least 2 logs more effective than when either component is absent.

Enables antibacterial performance using derivatized chitosan meeting defined structural and physicochemical constraints, including molecular weight and polydispersity index ranges.

Supports treating bacterial infections with synergistic/sensitizing effects when used with antibacterial agents.

Aims to inhibit MDR transfer and/or acquisition of MDR and reduce transmission and MDR bacterial load.

Documented Applications

Inhibiting the growth of a bacterium or killing a bacterium in a subject using derivatized chitosan together with an anti-bacterial agent in an effective combined amount.

Antibacterial use against MDR bacteria, including MRSA and other listed bacteria, using the derivatized chitosan combined with an anti-bacterial agent.

Antibacterial combinations using agents selected from Ciprofloxacin, Rifampicin, Neomycin, silver, or Gentamicin against Pseudomonas aeruginosa.

Inhibiting multiple drug resistance (MDR), including inhibiting MDR transfer by MDR bacteria and/or inhibition of acquisition of MDR by non-MDR bacteria.

Combined treatment of bacterial infections with antibacterial agents to provide synergistic/sensitizing effects.

Reducing transmission and MDR bacterial load.

Protective contexts including wound dressing and medical device use.

Medical-device/contact and cystic fibrosis (CF) lung biofilm viscosity reduction with chitosan-arginine.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.